Monday, 26 July 2021
Anti-PD-1/PD-L1 immunotherapy is promising for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut microbiota plays a crucial role in immunotherapy sensitization and Panax ginseng has been shown to possess immunomodulatory potential. In this study, we aimed to investigate whether the combination treatment of ginseng polysaccharides (GPs) and αPD-1 mAb could sensitize the response by modulating gut microbiota.
Syngeneic mouse models were administered GPs and αPD-1 mAb, and the sensitizing anti-tumor effects of the combination treatment on gut microbiota were further assessed by fecal microbiota transplantation (FMT) and 16S rRNA sequencing. To assess the immune-related metabolites, metabolomics analysis of the plasma samples was performed.
Attend this webinar to hear from:
Complete the form to register for the webinar
Elaine Leung, Ph.D.
Associate Professor, State Key Laboratory of Quality Research in Chinese Medicine
Macau University of Science and Technology
Mark D. Driscoll, Ph.D.
Chief Scientific Officer
Khi Pin Chua, Ph.D.
Field Applications Scientist, Bioinformatics